There is no cure for idiopathic pulmonary fibrosis (IPF) but a number of potential pharmacological treatment options and therapeutic strategies for patients to manage their condition exist. As the clinical course of IPF is highly variable between patients, management of the disease may also vary considerably between patients. Management strategies may include pharmacologic therapies, long-term oxygen treatment, pulmonary rehabilitation, lung transplantation or participation in clinical trials.
In 2011, clinical guidelines for the management of idiopathic pulmonary fibrosis (IPF) were developed by an international collaboration of major respiratory societies in the US (ATS), Europe (ERS), Japan (JRS) and Latin America (ALAT). Together, these professional bodies reviewed the clinical evidence base, and made recommendations about pharmacologic treatment options and therapeutic strategies for patients with IPF.1
The 2015 “Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis” was published in July 2015, updating treatment recommendations according to evidence reported since the publication of the prior guideline in 2011 (see sections below).2
Watch the IPF webinar: Update of the IPF treatment guidelines in 2015 with Prof Jürgen Behr and Prof Carlo Vancheri
A number of non-pharmacologic therapies (addressed only in 2011) are recommended for patients with IPF:1